Trial Profile
Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteolysis
- Focus Therapeutic Use
- 03 Jul 2021 Status changed from active, no longer recruiting to completed.
- 06 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.